Every treatment plan is personalised. Dr Ashwin K.R. reviews your scans, pathology and, where relevant, biomarker results with a multidisciplinary team, then recommends a sequence of treatment that fits your cancer and your health.
Common questions, answered
Liver, pancreas and bile duct questions answered →Hepatobiliary and pancreatic (HPB) cancer is the group of cancers that start in the liver, bile ducts, gallbladder, pancreas and ampulla of Vater, the organs that produce and deliver bile and digestive enzymes.
The main HPB cancers are pancreatic adenocarcinoma, hepatocellular carcinoma, cholangiocarcinoma, gallbladder cancer, ampullary cancer and pancreatic neuroendocrine tumors, along with cancers that spread to the liver from elsewhere.
| Cancer Type | Where It Starts | Key Facts |
|---|---|---|
| Pancreatic ductal adenocarcinoma (PDAC) | Cells lining the pancreatic ducts | Most common pancreatic cancer (about 90%); often diagnosed late |
| Pancreatic neuroendocrine tumor (PNET) | Hormone-producing cells of the pancreas | Usually slower-growing; may produce hormones causing symptoms |
| Hepatocellular carcinoma (HCC) | Main liver cells (hepatocytes) | Most common primary liver cancer; often linked to cirrhosis or hepatitis |
| Intrahepatic cholangiocarcinoma | Bile ducts inside the liver | Often presents as a liver mass |
| Perihilar cholangiocarcinoma (Klatskin tumor) | Bile ducts where they leave the liver | Commonly causes jaundice; complex surgery |
| Distal cholangiocarcinoma | Bile duct near the pancreas | Usually treated with the Whipple procedure |
| Gallbladder cancer | Gallbladder | Strongly linked to gallstones; sometimes found after gallbladder removal |
| Ampullary cancer | Ampulla of Vater (where bile and pancreatic ducts open) | Causes jaundice early, so often found at a more treatable stage |
| Liver metastases | Cancer spread from bowel, breast or other organs | Colorectal liver metastases can be curable with surgery in selected patients |
HPB cancer can be cured in some patients, most often when the tumor is found before it has spread and can be completely removed with surgery, usually combined with chemotherapy.
HPB cancers are often diagnosed late because the liver, pancreas and bile ducts lie deep inside the abdomen, and early tumors usually cause no symptoms or only vague ones.
Research generally links complex pancreatic and liver surgery at high-volume centres with specialist HPB surgeons to lower complication and mortality rates.
Commonly reported symptoms of pancreatic cancer include painless jaundice, upper abdominal pain spreading to the back, unexplained weight loss and new-onset diabetes; early tumors often cause no symptoms, and many of these symptoms have non-cancer causes.
Liver, bile duct and gallbladder cancers most often cause jaundice, pain in the upper right abdomen, weight loss and, in people with cirrhosis, a sudden worsening of liver function.
| Symptom | Liver Cancer (HCC) | Bile Duct Cancer | Gallbladder Cancer | Pancreatic Cancer |
|---|---|---|---|---|
| Jaundice | Possible | Very common | Common | Common (head of pancreas) |
| Itching, dark urine, pale stools | Possible | Very common | Common | Common |
| Right upper abdominal pain | Common | Common | Very common | Less common |
| Back pain | Uncommon | Uncommon | Uncommon | Common |
| Lump or swelling in the abdomen | Possible | Uncommon | Possible | Uncommon |
| Fluid in the abdomen (ascites) | Common | Advanced disease | Advanced disease | Advanced disease |
| New or worsening diabetes | Uncommon | Uncommon | Uncommon | Possible warning sign |
| Fever with chills (cholangitis) | Uncommon | Possible | Possible | Possible |
| Weight loss and fatigue | Common | Common | Common | Very common |
Jaundice is not always caused by cancer; gallstones, hepatitis and other liver conditions are more common causes, but jaundice always needs prompt medical assessment.
HPB cancers usually develop from a combination of long-term inflammation, genetic changes and lifestyle or environmental factors, and in many patients no single cause can be identified.
| Risk Factor | Cancers Most Linked |
|---|---|
| Chronic hepatitis B or C infection | Liver cancer (HCC), intrahepatic cholangiocarcinoma |
| Cirrhosis from any cause | Liver cancer (HCC) |
| Fatty liver disease (MASLD/NASH), obesity, diabetes | Liver cancer, pancreatic cancer |
| Alcohol | Liver cancer, pancreatic cancer (via chronic pancreatitis) |
| Tobacco (smoking and chewing) | Pancreatic cancer, bile duct cancer |
| Gallstones, especially large or long-standing | Gallbladder cancer |
| Chronic pancreatitis | Pancreatic cancer |
| Primary sclerosing cholangitis (PSC) | Bile duct cancer, gallbladder cancer |
| Choledochal cysts; liver fluke infection | Bile duct cancer |
| Aflatoxin (mould on poorly stored grains and nuts) | Liver cancer |
| Inherited gene changes (BRCA2, PALB2, Lynch syndrome, others) | Pancreatic and bile duct cancers |
Most pancreatic cysts are not cancer, but some types, particularly mucinous cysts such as IPMN and MCN, can become cancerous over time and need specialist monitoring or surgery.
| Cyst Type | Cancer Risk | Usual Approach |
|---|---|---|
| Pseudocyst (after pancreatitis) | Not pre-cancerous | Observation or drainage if symptomatic |
| Serous cystadenoma | Very low | Observation; surgery only if large or causing symptoms |
| Branch-duct IPMN | Low to moderate | Regular MRI/EUS surveillance; surgery if high-risk features appear |
| Main-duct IPMN | High | Surgery usually recommended if fit |
| Mucinous cystic neoplasm (MCN) | Moderate | Surgery often recommended |
| Solid pseudopapillary neoplasm (SPN) | Low-grade malignant potential | Surgery usually recommended |
An estimated 5β10% of pancreatic cancers are linked to inherited gene changes, and international guidelines, including NCCN, recommend offering germline genetic testing to everyone diagnosed with pancreatic cancer.
HPB cancer is diagnosed and staged with high-quality cross-sectional imaging, blood tests and, in most cases, a biopsy, which together show the cancer type, its extent and whether it can be removed.
| Step | Test | Why It Is Done |
|---|---|---|
| 1 | Liver function tests and blood counts | Assess jaundice, liver health and fitness for treatment |
| 2 | Triple-phase / pancreatic-protocol CT scan | Main test for tumor size, blood vessel involvement and spread |
| 3 | MRI with MRCP | Detailed view of the liver, bile ducts and pancreatic duct |
| 4 | Endoscopic ultrasound (EUS) with biopsy | Close-up imaging of the pancreas and bile duct; tissue sampling |
| 5 | ERCP with brushings or stent | Obtains cells from the bile duct and relieves jaundice when needed |
| 6 | Tumor markers (CA 19-9, CEA, AFP) | Support diagnosis, assess prognosis and monitor response |
| 7 | PET-CT or Ga-68 DOTATATE PET | Looks for hidden spread; DOTATATE PET for neuroendocrine tumors |
| 8 | Staging laparoscopy | Checks for small deposits on the abdominal lining before major surgery |
| 9 | Biomarker and genetic testing | Identifies targets for precision treatment |
Most HPB diagnostic tests take under an hour, usually require a few hours of fasting, and report results within a few days to two weeks.
Table: Diagnostic test logistics for HPB cancer
| Test | Time Needed | Preparation | Typical Result Time |
|---|---|---|---|
| Pancreatic-protocol CT scan | 15β30 minutes | Fast about 4 hours; kidney function test for contrast | 1β2 days |
| MRI with MRCP | 30β60 minutes | Fast 4β6 hours; declare metal implants or pacemaker | 1β2 days |
| Endoscopic ultrasound (EUS) | 30β60 minutes | Fast 6β8 hours; review blood thinners; bring an escort | Findings same day; biopsy 3β7 days |
| ERCP | 30β90 minutes | Fast 6β8 hours; blood clotting tests; usually a short hospital stay | Stent same day; brushings 3β7 days |
| PET-CT scan | 2β3 hours in total | Fast about 6 hours; blood sugar check; avoid strenuous exercise | 1β2 days |
| Liver biopsy (image-guided) | 30β60 minutes plus 4β6 hours observation | Clotting tests; stop blood thinners as advised | 3β7 working days |
| Biomarker / genetic testing | Not applicable | Uses biopsy tissue or a blood sample | 1β3 weeks |
Typical timeframes only; always follow the instructions given for your appointment.
A biopsy is usually needed before chemotherapy or radiation, but some patients may proceed directly to surgery, or be diagnosed without a biopsy, when imaging findings are typical.
A raised CA 19-9 does not by itself confirm pancreatic cancer, because it can also be raised by jaundice, bile duct blockage, pancreatitis and other conditions.
Not every jaundiced patient needs a stent before surgery; biliary drainage is usually reserved for those with bile duct infection, severe itching, very high bilirubin, or who will receive chemotherapy or face a delay before surgery.
Table: Biliary stent and drainage options at a glance
| Option | How It Is Placed | Typical Duration Before Review or Exchange | Typical Hospital Time |
|---|---|---|---|
| Plastic ERCP stent | Through an endoscope passed via the mouth | Often exchanged about every 3 months | Day procedure or overnight stay |
| Metal ERCP stent (SEMS) | Through an endoscope passed via the mouth | Often remains open for many months | Day procedure or overnight stay |
| P drain | Through the skin into the liver under imaging guidance | Weeks to months; may be converted to an internal stent | 1β3 days |
| EUS-guided biliary drainage | Through an endoscope with ultrasound guidance | Often similar to a metal stent | 1β2 days |
Stent lifespan varies from patient to patient. Fever, chills or returning jaundice may mean a blocked stent and need same-day review.
For most patients, HPB cancer treatment begins within about two to four weeks of diagnosis, once staging is complete and the tumor board has agreed a plan.
Table: Typical patient journey from first visit to treatment
| Stage | What Happens | Typical Timeframe |
|---|---|---|
| First consultation | History, examination, review of existing scans and reports | Week 1 |
| Diagnostic and staging tests | CT/MRI, EUS or ERCP, biopsy, blood tests | Weeks 1β2 |
| Jaundice relief (if needed) | Biliary stent or drainage | Within days, as needed |
| Tumor board review | Resectability and treatment plan agreed | Weeks 2β3 |
| Pre-treatment optimisation | Nutrition, fitness, diabetes and liver function assessment | Weeks 2β3 |
| Treatment start | Surgery, chemotherapy or liver-directed therapy begins | Weeks 2β4 |
Timelines vary with test availability and your health.
Biomarker testing identifies molecular changes in HPB cancers that can make you eligible for targeted therapy, immunotherapy or clinical trials, and it is especially valuable in bile duct and pancreatic cancer.
| Biomarker | Relevant Cancers | What It Can Mean for Treatment |
|---|---|---|
| BRCA1/2, PALB2 (germline) | Pancreatic | May predict platinum sensitivity; possible olaparib maintenance |
| KRAS (including G12C) | Pancreatic | Present in about 90%; KRAS G12C and KRAS wild-type tumors may have targeted options or trials |
| NTRK, NRG1, BRAF, RET fusions/mutations | Pancreatic, biliary | Rare but potentially targetable |
| FGFR2 fusions | Intrahepatic cholangiocarcinoma | Possible eligibility for FGFR inhibitors (e.g., pemigatinib, futibatinib) |
| IDH1 mutations | Intrahepatic cholangiocarcinoma | Possible eligibility for ivosidenib |
| HER2 amplification | Gallbladder, bile duct | Possible eligibility for HER2-directed therapy |
| MSI-H / dMMR, high TMB | All HPB cancers | Often associated with strong responses to immunotherapy |
| Somatostatin receptor status | Neuroendocrine tumors | Eligibility for somatostatin analogues and PRRT |
Drug approvals and availability vary by country. Your oncologist will advise which options apply to you.
For HPB cancers, the most practical question is resectability, meaning whether the tumor can be completely removed, which depends on its involvement of major blood vessels, spread and your liver function and fitness.
| Pancreatic Cancer Category | What It Means | Usual Treatment Approach |
|---|---|---|
| Resectable | No significant contact with major arteries or veins; no distant spread | Surgery, usually with chemotherapy before and/or after |
| Borderline resectable | Limited contact with blood vessels that may be reconstructed | Chemotherapy (sometimes radiation) first, then surgery if the response is good |
| Locally advanced | Extensive involvement of major arteries; no distant spread | Chemotherapy Β± radiation; surgery reconsidered in selected responders |
| Metastatic | Spread to the liver, lungs or abdominal lining | Systemic therapy and supportive care |
Liver cancer is most commonly staged using the Barcelona Clinic Liver Cancer (BCLC) system, which considers tumor burden, liver function and overall health to guide treatment.
| BCLC Stage | Description | Common Treatment Options |
|---|---|---|
| 0 (very early) | Single tumor under 2 cm; good liver function | Resection or ablation |
| A (early) | Single tumor, or up to 3 tumors each 3 cm or less | Resection, ablation or liver transplant |
| B (intermediate) | Multiple tumors in the liver; no vessel invasion or spread | TACE or TARE; transplant in selected cases; systemic therapy |
| C (advanced) | Blood vessel invasion or spread outside the liver | Immunotherapy combinations and targeted therapy |
| D (end stage) | Severely reduced liver function or poor general health | Supportive care; transplant only if criteria are met |
Survival rates for HPB cancers vary widely by cancer type and stage, and they are generally much higher when the cancer is found before it spreads and can be removed.
| Cancer Type | Localized | Regional Spread | Distant Spread | All Stages |
|---|---|---|---|---|
| Gallbladder cancer | ~69% | ~28% | ~3% | ~20% |
| Pancreatic cancer | ~44% | ~16% | ~3% | ~13% |
| Liver cancer (incl. intrahepatic bile duct) | ~37% | ~13% | ~3% | ~22% |
| Intrahepatic bile duct cancer | ~23% | ~9% | ~3% | ~9% |
| Extrahepatic bile duct cancer | ~18% | ~17% | ~2% | ~11% |
Approximate 5-year relative survival based on US SEER data as reported by the American Cancer Society. These figures describe past patients and cannot predict an individual outcome.
Stage 4 pancreatic and liver cancer are generally not curable, but they are treatable, and chemotherapy, immunotherapy and targeted therapy can often slow the cancer, relieve symptoms and extend life.
HPB cancer is treated with surgery, chemotherapy, radiation therapy, immunotherapy, targeted therapy, liver-directed procedures and liver transplantation, often in combination and tailored by a multidisciplinary tumor board.
The Whipple procedure (pancreaticoduodenectomy) is the standard operation for cancers of the pancreatic head, ampulla and lower bile duct, and it is one of several specialised HPB operations chosen according to tumor location.
| Surgery | Used For | What Is Removed or Reconstructed |
|---|---|---|
| Whipple procedure / pylorus-preserving pancreaticoduodenectomy | Pancreatic head, ampullary, distal bile duct and some duodenal cancers | Head of pancreas, duodenum, gallbladder and lower bile duct; pancreas, bile duct and stomach reconnected to the intestine |
| Distal pancreatectomy | Tumors in the body or tail of the pancreas | Body and tail of pancreas, usually with the spleen |
| Total pancreatectomy | Tumors involving the whole pancreas or extensive IPMN | Entire pancreas; lifelong insulin and enzyme replacement needed |
| Vascular resection and reconstruction | Tumors involving the portal or superior mesenteric vein | Affected vein segment removed and repaired during pancreatic surgery |
| Minor or major hepatectomy | Liver cancer, intrahepatic cholangiocarcinoma, liver metastases | Segments or a whole side (lobe) of the liver; the rest regrows |
| Bile duct resection with hepaticojejunostomy | Perihilar cholangiocarcinoma | Bile ducts, often with part of the liver; bile ducts joined to the intestine |
| Radical (extended) cholecystectomy | Gallbladder cancer | Gallbladder, adjacent liver and regional lymph nodes |
| Liver transplantation | Selected early HCC with cirrhosis; selected perihilar cholangiocarcinoma | Entire diseased liver replaced with a donor liver |
The Whipple procedure is a major operation with a significant risk of complications, but at experienced high-volume centres the risk of death is generally low, and many complications can be managed without further surgery.
Preparing for HPB surgery over the two to four weeks beforehand, through exercise, nutrition and medication review, can help lower the risk of complications and speed up recovery.
Table: Preparation timeline before HPB surgery
| When | What to Do | Why It Helps |
|---|---|---|
| 2β4 weeks before | Walk daily; do breathing exercises; eat a high-protein diet; stop smoking and alcohol | Builds fitness and lowers the risk of lung and wound complications |
| 1β2 weeks before | Pre-anaesthesia check, blood tests and review of medicines, including blood thinners and diabetes medicines | Reduces bleeding and anaesthesia risks |
| A few days before | Arrange support at home for after discharge; confirm admission time | Makes the return home smoother |
| Night before | Follow fasting instructions; take a carbohydrate drink only if advised | Safe anaesthesia; supports faster recovery (ERAS) |
| Day of surgery | Bring your medication list, reports, scans and ID | Ensures your team has complete information |
Always follow the specific instructions from your surgical and anaesthesia teams.
The liver can regenerate, and surgeons can often remove a large portion of a healthy liver, provided enough functioning liver remains, usually at least 20β30% of a normal liver or around 40% in a liver damaged by cirrhosis or chemotherapy.
Table: Typical timeline for portal vein embolization (PVE) before liver surgery
| Step | What Happens | Typical Timing |
|---|---|---|
| CT volumetry | Measures how much liver will remain after surgery | During surgical planning |
| Portal vein embolization | A radiologist blocks the portal vein branch to the part of the liver to be removed, through a needle | Day procedure or 1β2 night stay |
| Repeat CT volumetry | Checks how much the remaining liver has grown | About 3β6 weeks after PVE |
| Liver resection | Surgery goes ahead if the remaining liver has grown enough | Often 4β8 weeks after PVE |
Liver transplantation may be an option for patients with early-stage liver cancer and cirrhosis who meet established criteria, such as the Milan criteria, because it removes both the cancer and the diseased liver.
Chemotherapy before or after pancreatic surgery treats microscopic cancer cells that surgery alone cannot remove, and clinical trials have shown that it improves survival compared with surgery alone.
Chemotherapy and immunotherapy for HPB cancer are given in cycles, most commonly every two to four weeks, and curative courses typically last about six months.
Table: Common HPB cancer treatment schedules
| Regimen | Used For | How Often | Typical Course Length |
|---|---|---|---|
| Modified FOLFIRINOX (adjuvant) | Pancreatic cancer after surgery | Every 2 weeks | About 6 months (12 cycles) |
| Gemcitabine + capecitabine (adjuvant) | Pancreatic cancer after surgery | Gemcitabine days 1, 8, 15; capecitabine days 1β21 of each 28-day cycle | About 6 months |
| Capecitabine (adjuvant) | Bile duct and gallbladder cancer after surgery | Days 1β14 of each 21-day cycle | About 6 months (8 cycles) |
| Gemcitabine + nab-paclitaxel | Advanced pancreatic cancer | Days 1, 8, 15 of each 28-day cycle | Continued while effective and tolerated |
| Gemcitabine + cisplatin + durvalumab | Advanced biliary tract cancer | Days 1 and 8 of each 21-day cycle | Up to 8 cycles, then durvalumab every 4 weeks |
| Atezolizumab + bevacizumab | Advanced liver cancer (HCC) | Every 3 weeks | Continued while effective and tolerated |
| Lutetium-177 dotatate (PRRT) | Somatostatin receptor-positive NETs | Every 8 weeks | Usually 4 treatments |
Examples only. Your regimen, doses and number of cycles will be individualised by your oncologist.
Immunotherapy and targeted therapy are now part of standard care for many advanced liver and biliary tract cancers, and for pancreatic cancers with specific biomarkers.
| Cancer | Immunotherapy / Targeted Options (examples) |
|---|---|
| Liver cancer (HCC) | Atezolizumab + bevacizumab; durvalumab + tremelimumab; lenvatinib; sorafenib; regorafenib and cabozantinib after progression |
| Biliary tract cancer | Durvalumab or pembrolizumab with chemotherapy; FGFR2 inhibitors; ivosidenib (IDH1); HER2-directed therapy |
| Pancreatic adenocarcinoma | Olaparib maintenance (germline BRCA); immunotherapy for MSI-H tumors; NTRK inhibitors for NTRK fusions |
| Pancreatic neuroendocrine tumors | Somatostatin analogues (octreotide, lanreotide); everolimus; sunitinib; PRRT |
Drug approvals and availability vary by country.
Liver-directed therapies treat tumors inside the liver without major surgery, and they are used when surgery is not suitable, to control disease, or to shrink tumors before transplant.
| Treatment | How It Works | Typically Used For |
|---|---|---|
| Radiofrequency / microwave ablation | A needle heats and destroys the tumor | Small tumors, usually up to about 3 cm |
| TACE (chemoembolization) | Chemotherapy injected into the tumorβs artery, then the artery is blocked | Intermediate-stage HCC; bridge to transplant |
| TARE / Y-90 radioembolization | Radioactive microspheres delivered to the tumor through its artery | HCC, including some with portal vein involvement; liver metastases |
| SBRT | High-precision radiation in 3β5 sessions | Tumors unsuitable for ablation or surgery |
In selected patients, cancer that has spread to the liver can be removed with surgery; liver metastases from colorectal cancer in particular are often treated this way, and a meaningful proportion of these patients achieve long-term survival.
The most common complications after HPB surgery are pancreatic fistula, delayed stomach emptying, bile leak, infection and bleeding, and many can be treated with drains, medicines or minimally invasive procedures.
| Complication | What It Is | How It Is Usually Managed |
|---|---|---|
| Pancreatic fistula (leak) | Pancreatic juice leaks from the join between pancreas and intestine | Surgical drains; radiology-guided drainage; nutrition support |
| Delayed gastric emptying | The stomach is slow to empty after a Whipple | Temporary feeding tube or medicines; usually resolves in weeks |
| Bile leak | Bile escapes from the liver surface or bile duct join | Drainage; ERCP stent in some cases |
| Post-hepatectomy liver failure | The remaining liver struggles to function | Intensive support; prevention through careful planning |
| Bleeding | Early or delayed bleeding from vessels | Blood transfusion; interventional radiology embolization; surgery if needed |
| Infection / abscess | Collection of infected fluid | Antibiotics and image-guided drainage |
| Diabetes | Reduced insulin production after pancreatic surgery | Diet, tablets or insulin as needed |
Hospital stay after HPB cancer surgery commonly ranges from about four to fourteen days, depending on the operation, the surgical approach and whether complications occur.
Table: Typical hospital stay and recovery after HPB procedures
| Procedure | Typical Hospital Stay | Return to Light Activity | Typical Return to Desk Work |
|---|---|---|---|
| Liver ablation (RFA/MWA) | 1β2 days | Within 1 week | 1β2 weeks |
| TACE / TARE | 1β2 days | Within 1 week | 1β2 weeks |
| Minor liver resection (laparoscopic) | 3β5 days | 2β3 weeks | 4β6 weeks |
| Major liver resection (open) | 6β10 days | 4β6 weeks | 2β3 months |
| Whipple procedure | 7β14 days | 4β6 weeks | 2β3 months |
| Distal pancreatectomy | 5β7 days | 3β4 weeks | 6β8 weeks |
| Radical cholecystectomy | 4β7 days | 2β4 weeks | 4β8 weeks |
| Liver transplantation | 2β3 weeks | 6β8 weeks | 3β6 months |
Complications may lengthen these times.
Side effects from HPB cancer treatment are common but mostly temporary, and supportive medicines can prevent or reduce many of them.
| Side Effect | Common With | How It Is Managed |
|---|---|---|
| Nausea, vomiting | FOLFIRINOX, cisplatin | Preventive anti-nausea medicines |
| Fatigue | Most treatments | Gentle activity, rest, treating anemia |
| Low blood counts / infection risk | FOLFIRINOX, gemcitabine | Regular blood tests; growth factor injections |
| Tingling or numbness (neuropathy) | Oxaliplatin, nab-paclitaxel | Dose adjustment; avoid cold exposure with oxaliplatin |
| Diarrhea | FOLFIRINOX, capecitabine | Medicines and hydration |
| Hand-foot syndrome | Capecitabine, sorafenib, lenvatinib | Moisturisers, dose adjustment |
| High blood pressure, bleeding risk | Bevacizumab, lenvatinib | Blood pressure monitoring; endoscopy for varices before bevacizumab |
| Immune-related inflammation | Immunotherapy | Early reporting; steroids when necessary |
Contact your care team immediately, or go to the nearest emergency department, if you develop fever, chills, new or worsening jaundice, severe abdominal pain, bleeding or breathing difficulty.
Table: When to seek help during HPB cancer treatment
| Symptom | What to Do | Urgency |
|---|---|---|
| Fever of 38Β°C (100.4Β°F) or higher, or shivering | Call the 24-hour oncology helpline or go to the emergency department | Immediately |
| Fever with jaundice (possible stent blockage or cholangitis) | Go to the emergency department | Immediately |
| Vomiting blood, black stools or bleeding from a drain | Go to the emergency department | Immediately |
| Severe or sudden abdominal pain | Go to the emergency department | Immediately |
| Breathlessness or chest pain | Call emergency services | Immediately |
| Returning yellow skin or eyes, dark urine | Call your HPB team | Same day |
| Unable to keep fluids down for 24 hours | Call the oncology helpline | Same day |
| Very high or very low blood sugar readings | Call your team or diabetes nurse | Same day |
| Oily stools, bloating, weight loss | Mention to your dietitian or doctor | Next visit or within a week |
24-hour oncology helpline: +91 88840 09955. In a life-threatening emergency, call your local emergency number.
After pancreatic surgery, dietitians commonly recommend small, frequent, protein-rich meals taken with pancreatic enzyme capsules, because the pancreas may no longer produce enough enzymes to digest food.
Pancreatic enzyme replacement therapy (PERT) replaces the digestive enzymes your pancreas can no longer make, and it works only when taken with food.
Diabetes can develop or worsen after pancreatic surgery, particularly after removal of the body and tail or the whole pancreas, and it requires monitoring and treatment.
| Operation | Diabetes Risk | Typical Management |
|---|---|---|
| Whipple procedure | Moderate; some patients develop new diabetes | Blood sugar monitoring; tablets or insulin if needed |
| Distal pancreatectomy | Higher, depending on how much pancreas is removed | Monitoring; insulin in some patients |
| Total pancreatectomy | Certain; lifelong insulin required | Insulin and specialist diabetes education |
A balanced, protein-rich diet supports liver recovery, and many patients with liver cancer do not need to restrict protein; your team will advise if you do.
Follow-up after HPB cancer treatment is most frequent in the first two years, when the risk of recurrence is highest, and usually includes clinical review, tumor markers and CT or MRI scans.
Table: Typical follow-up schedule after curative HPB cancer treatment
| Time After Treatment | Visit Frequency | Typical Tests |
|---|---|---|
| Years 1β2 | Every 3β6 months | Clinical review; CA 19-9, CEA or AFP; CT or MRI scan |
| Years 3β5 | Every 6β12 months | Clinical review; tumor markers; imaging as indicated |
| After 5 years | Yearly | Clinical review; diabetes, nutrition and vitamin checks |
| After liver transplant | Lifelong, per transplant programme | Immunosuppression levels; AFP and imaging for recurrence |
Recurrence is a real risk after HPB cancer surgery, especially for pancreatic and bile duct cancers, and it depends on stage, lymph node involvement, surgical margins and response to chemotherapy.
Many patients regain most of their energy within two to three months of major HPB surgery, although full recovery, especially after the Whipple procedure, can take longer.
Recovery after major HPB surgery usually follows a predictable sequence, from walking on the first day to starting chemotherapy within about two to three months, although each patient progresses at their own pace.
Table: Typical recovery milestones after Whipple or major liver surgery
| Time After Surgery | What Typically Happens |
|---|---|
| Day 1 | Sitting out of bed, sips of fluid and a short walk with support |
| Days 2β5 | Soft diet begins; drains and urinary catheter reviewed and often removed |
| Days 7β14 | Discharge home for many patients |
| Weeks 2β3 | First clinic visit; wound check; final pathology results discussed |
| Weeks 4β6 | Light daily activities; driving only when off strong painkillers and cleared by your team |
| Weeks 8β12 | Adjuvant chemotherapy often starts, if recommended |
| Months 2β3 | Return to desk work for many patients |
Complications or slower recovery may extend these timeframes.
Palliative care does not mean giving up; it is specialist medical care that relieves symptoms and improves quality of life at any stage of cancer, and it can be given alongside active treatment.
Jaundice, itching and bowel blockage in advanced HPB cancer can often be relieved with minimally invasive stents, drainage or bypass procedures.
| Problem | Treatment Options |
|---|---|
| Jaundice from bile duct blockage | ERCP metal stent; percutaneous biliary drainage (P); EUS-guided biliary drainage |
| Severe itching | Relieving the blockage; medicines such as cholestyramine or rifampicin |
| Blockage of the stomach outlet or duodenum | Duodenal stent; EUS-guided gastrojejunostomy; surgical bypass |
| Fluid in the abdomen (ascites) | Paracentesis; indwelling drainage catheter; diuretics |
| Pancreatic cancer pain | Pain medicines; celiac plexus block or neurolysis; radiation |
| Bleeding from a tumor | Endoscopic therapy; embolization; radiation |
A second opinion from a specialist HPB team can be worthwhile when surgery has been ruled out, because resectability assessments can differ between centres, and some patients may become eligible for surgery after further review or chemotherapy.
Bring every scan, report and biopsy sample related to your diagnosis, because HPB decisions depend heavily on detailed review of the original images.
Table: Documents checklist for your HPB cancer consultation
| Item | Why It Is Needed | Format |
|---|---|---|
| CT and MRI scan images | Our radiologists and surgeons review blood vessel involvement directly | Images on CD/DVD or online link (not only reports) |
| Biopsy, cytology or brushing reports | Confirms diagnosis; allows biomarker testing | Reports, plus slides and blocks from the lab |
| EUS and ERCP reports | Shows tumor details and any stent placed | Printed reports with stent type and date |
| Blood tests (LFTs, CA 19-9, AFP, CEA) | Liver function and tumor marker trends | All available results, with dates |
| Hepatitis and cirrhosis records | Liver function affects treatment choices | Reports from your hepatologist |
| Medication list | Blood thinners, diabetes medicines and interactions | Names, doses and timing |
| Previous treatment summaries | Shows chemotherapy or procedures already done | Discharge and treatment summaries |
| ID and insurance documents | Needed for registration and approvals | Government ID; insurance card or policy |
Clinical trials give eligible patients access to promising new treatments under close monitoring, and they are especially important in pancreatic and bile duct cancer, where new therapies are actively being developed.
The most useful questions cover your exact diagnosis, whether the tumor can be removed, the goal of treatment, the risks of surgery and your teamβs experience.
Feeling shock, fear or sadness after an HPB cancer diagnosis is normal, and professional emotional support is an important part of cancer care.
Not every HPB cancer can be prevented, but the risk of many can be lowered by preventing and treating hepatitis, protecting liver health, avoiding tobacco and managing gallstone disease appropriately.
Most people with gallstones that cause no symptoms do not need surgery, but gallbladder removal (cholecystectomy) is generally advised for symptomatic gallstones and for certain findings linked to higher cancer risk.
Surveillance is generally recommended for people at higher risk, including those with cirrhosis, chronic hepatitis B, high-risk pancreatic cysts or inherited gene changes linked to pancreatic cancer.
Table: Surveillance recommendations for high-risk groups
| High-Risk Group | Recommended Surveillance | Typical Interval |
|---|---|---|
| Cirrhosis from any cause | Liver ultrasound, with or without AFP | Every 6 months |
| Chronic hepatitis B (certain groups, even without cirrhosis) | Liver ultrasound, with or without AFP | Every 6 months |
| Branch-duct IPMN or other mucinous cyst | MRI/MRCP and/or EUS | Every 6β24 months, depending on size and features |
| BRCA2, PALB2, CDKN2A, Lynch or strong family history of pancreatic cancer | Pancreatic MRI and/or EUS in expert centres | Usually yearly |
| Primary sclerosing cholangitis (PSC) | MRI/MRCP and CA 19-9; gallbladder ultrasound | Usually every 6β12 months |
| Gallbladder polyps under 10 mm | Ultrasound | Per specialist advice, often at 6 months, 1 year and 2 years |
If you or a loved one has been diagnosed with, or is being tested for, liver, pancreatic, bile duct or gallbladder cancer, our HPB team can guide you through diagnosis, treatment, recovery and beyond.
Medical disclaimer: This information is for general education and does not replace personalised medical advice. Please consult a qualified oncologist or HPB surgeon about your specific diagnosis and treatment.
Medically reviewed by Dr Ashwin K.R. Β· Last reviewed: 10 October 2026
Medical disclaimer: This information is for general education and does not replace personalised medical advice. Please consult a qualified doctor about your specific diagnosis and treatment.